

DAFTAR PUSTAKA

Abboud, H., Henric, W.L. 2010. Stage IV chronic kidney disease. *N Eng J Med.* 362(1):56-62

Babitt, J. L., Lin, H. Y. 2012. Mecanisms of anemia in CKD. *J Am Soc Nephrol.* 23(10): 1631-1634

Behzad, B.A., Mafi, N.A., Tabei, S.Z., Lankarani, K.B., Torab, A., Moaddeb, A. 2006. Anti-HBc and HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. *Indian J Med Res.* 123(1):37-42.

Black, J & Hawks, J. 2009. *Medical surgical nursing: clinical management for positive outcome 8th edition.* Elseiver: Singapore.

Bootman, J.L., Townsend, R.J., Mcghan, W.F. 1996. *Principles of Pharmacoeconomics.* Harvard Whitney Books Company: USA, pp: 6-9.

Couser, W. G., Remuzzi, G., Mendis, S., Tonelli, M. 2011. The contribution of chronic kidney disease to the global burden of major noncommunicable disease. *Kidney Int.* 80(12): 1-13

Dalton, C., Schmidt, R. 2008. Diagnosis and treatment of anemia of chronic kidney disease in the primary care setting : a primer for nurse practitioners, *J Nur Pra.* 4(3):194-200.

Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B.G., Posey, L. M. 2011. *Pharmacotherapy: a pathophysiologic approach ninth edition.* McGraw-Hill: New York.

Falodia, J., Singla, M.K. 2012. Review article: CKD epidemiology and risk factors. Clinical queries: *Nephrology.* 249- 252

Fraser, S. D. S., Roderick, P. J., May, C. R., McIntyre, N., McIntire, C., Fluck, R. J., *et al.* 2015. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. *BMC Nephrol.* 193(16): 1-11

Gupta, A.K., David, W. 2014. Does erythropoietin cause hemoglobin variability- is it 'normal'? *PLoS One* 9(4): 1-8

Honeycutt, A. A., Segel, J. E., Zhuo, X., Hoerger, T.J., Imai, K., Williams, D. 2013. Medical cost of CKD in the medicare population. *J Am Soc Nephrol.* 24: 1478-1483

- Ignatavicius, D., Workman, M. L. 2010. *Medical-surgical nursing 6th ed.* Saunders Elsevier: St. Louis
- Jayaraman. R & Voort, J. V. 2010. Principles of management of chronic kidney disease. *Paediatrics and Child Health.* 20(6): 291-296.
- KDIGO. 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 3(1):1-150
- Kemenkes RI. 2014. *Penyajian pokok-pokok hasil riset kesehatan dasar 2013 Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.* Kementrian Kesehatan: Jakarta 71-74
- Kruep, E.J, Basskin, L.E. 2005. Cost-minimization analysis of darbepoietin alfa versus epoetin alfa in the hospital setting. *Am J Health Syst Pharm.* 62 (24): 2597-2603
- Lankhorst, C.E., Wish, J.B. 2010. Anemia in renal disease: diagnosis and management. *Blood Rev.* 24(1): 39-47
- Laliberte, F., Bookhart, B.K., Vakeman, F., Corral, M., Duh, M.S., Bayley, R.A., et al. 2009. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. *J Manag Care Pharm,* 15(4):312-322
- Lawler, E.V, Bradbury, B.D., Gagnon D.R. 2010. Transfusion burden among patients with chronic kidney disease and anemia. *Clin J Am Soc Nephrol,* 5(4):667-672.
- Lewis, S.M., Driksen, S.R., Heitkemper, M.M., Bucher, L., Harding M. 2014. *Medical-surgical nursing: assessment and management of clinical problem 9th ed.* Elsevier: St. Lois
- Manolis, A. S., Tzeis, S., Triantafyllou, K., Michaelidis, J., Phiros, I., Sakellaris, N., et al. 2005. Erythropoietin in heart failure and other cardiovascular disease: hematopoietic and pleiotropic effects. *Curr Drug Targets Cardiovasc Haematol Disord.* 5(5): 355-375
- Macdougall, I.C., Hutton, R.D., Cavill, I., Coles, G.A., Williams, J.D. 1990, Treating renal anemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. *Br Med J.* 300:655-659
- Maoujoud, O., Ahid, S., Cherrah, Y. 2016. The cost-utility of treating anemia with continuous erythropoietin receptor activator or epoetin versus routine blood transfusions among chronic hemodialysis patients. *Int J Nephrol Renovasc Dis* (9):35-43

- NKF KDOQI. 2010. National kidney foundation kidney disease outcomes quality initiative: clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. *Am J Kidney Dis* 39(1): 1-266
- Notopoero, P. B. 2007. Eritropoitin fisiologi, aspek klinik, dan laboratorik. *IJCP & ML*. 1(14):28-36
- Novoa, L. J. M., Salgado, C. M., Pena, A. B. R., Hernandez, F. J. R. 2010. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. *Pharmacol Ther*. 128(1): 61-81
- Page, D.E., House A. 1998. Important cost differences of blood transfusions and erythropoietin between hemodialysis and peritoneal dialysis patients. *Adv Perit Dial* 14: 87-95
- Pashos, C.L., Larhort, K., Fraser, K. A., McKenzie, R.S., Senbetta, M., Piech, C. T. 2012. Outcome of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. *Support Care Cancer*. 20: 159-165
- PERNEFRI. 2011. *Konsensus manajemen anemia pada penyakit ginjal kronik, perhimpunan nefrologi*. PERNEFRI: Jakarta 3-48
- PERNEFRI. 2016. *Report of Indonesia renal registry 8th edition*. PERNEFRI: Jakarta 1-45
- Sanchez, L. A. 2005. *Pharmacoeconomic: principles, methods and applications*, in Dipiro J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., Posey, M. L. *Pharmacotherapy: a pathophysiologic approach 6th edition*. McGrawHill: New York.
- Saran, K.A., Sabry, A. 2012. The cost of hemodialysis in a large hemodialysis center. *Saudi J Kidney Dis Transpl*. 23(1): 78-82
- Saran, R., Li, Y., Robinson, B., Ayanian, J., Balkrishnan, R., Gresham, J. B., *et al*. 2014. US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis*. 66(1): 1-305
- Smeltzer, S.C & Bone, B. G. 2010. *Handbook for Brunner and Suddarths Textbook of medical surgical nursing twelfth edition*. Lippincott: Philadelphia 587-593
- Smith, D. H., Gullion, C. M., Nichols, G., Keith, D. C., Brown, J. B. 2004. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. *J Am Soc Nephrol*. 15: 1300-1306
- Shavelle, R.M., Kenzie, R.M. 2012, Anemia and mortality in older persons: does the type of anemia affect survival? *Int J Hematol*. 95(3): 248-256.

- Smeltzer, S.C , Bare. 2010. *Textbook od Medical Surgical Nursing : In One Volume*. Lippincott Williams & Wilkins.
- Sukandar, E. Y., Andrajati, R., Sigit, J. I., Adnyana, I. K., Setiadi, A. A. P., Kusnandar, 2009. *ISO Farmakoterapi Edisi 2*. ISFI: Jakarta.
- Sun, J.H., Yu, R., Zhu, B., Wu, J., Larse, S., Zao, W., 2009. Hepatitis C infection and related factors and hemodialysis patients in China: systematic review and meta-analysis. *Ren Fail*. 31(7):610-620
- Stauffer, M.E. & Fan, T., 2014. Prevalence of anemia in chronic kidney disease in the United States. *PLoS One*. 9(1): 2–5
- Tandi, M., Kandou, P. R. D, Mongan, A. 2014. Hubungan antara derajat penyakit ginjal kronik dengan nilai agregasi trombosit. *Jurnal e-Biomedik*. 2(2):509-514
- Theml, H., Diem, H., Haferlach, T. 2004. *Color atlas of hematology practical microscopic and clinical diagnosis second edition*. Thime Stuttgart: New York 140-149
- Thomas, A. and Peterson, L.E. 2014. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. *Int J Nephrol Renovasc Dis* (7): 191–201
- Tonelli, M., Riella, M. 2014. Chronic kidney disease and the aging population. *Indian J Nephrol*. 24(2): 71-74
- Vogenberg, F.R., 2001. *Introduction to Applied Pharmacoeconomics*. McGraw-Hill: New York 1-5
- Walley, T., Haycox, A., Boland, A. 2004. *Pharmacoeconomics*. Churchill Livingstone: London 1-11
- Wilson, J. P., Rascati, K. L. 2001. *Pharmacoeconomics*, in Malone, P. M., Kier, K. L., Stanovich, J. E., Malone, M. J., *drug information: a guide for pharmacists 2th edition*. McGrawHill: New York
- Yani, F.R., Mukti, A.G., Sudjaswadi, R. 2010. Analisis biaya perawatan gagal ginjal kronik rawat inap sebagai pertimbangan dalam penetapan pembiayaan kesehatan berdasar INA-DRG di RSUD DR Moewardi. *JMPF* 1(2): 63-69
- Yang, M., Fox, C.H., Vassalotti, J., Choi, M. 2011. Complication of progression of CKD. *Adv Chronic Kidney Dis*. 18 (6): 400-405
- Zoccali, C., Kramer, A. and Jager, K. J. 2010. Chronic kidney disease and end stage renal disease-a review produced to contribute to the report the status of health in the European union: towards a healthier Europe. *NDT Plus*. 3(3): 213–224.